Kuchyne na miru

Regulatory

Jul 11, 2019
In the third in a series of articles summarizing efforts to put each of the “American Patients First” blueprint's four strategies into action, Rick Kelly and Nisha Desai focus on “Incentivizing Lower List Prices.”
Jul 11, 2019
Pharmaceutical Executive
New guidances open the door to interchangeables and less costly insulin.
Jul 11, 2019
Pharmaceutical Executive
What are we to make of the simmering public and political angst, asks Reflector
Jul 01, 2019
R&D organizations can leverage FDA’s final guidance on pre-approval information exchange, otherwise known as PIE, to engage with payers prior to regulatory approval and commercial launch.
Jun 25, 2019
A provision in a Senate health reform bill has reignited debate over the whether biological products should have to meet product quality standards established by the U.S. Pharmacopeia.
Jun 18, 2019
Congress is weighing in on drug pricing with a range of measures that differ in style and substance.
Jun 10, 2019
Pharmaceutical Executive
Cell and gene therapies in crosshairs of pricing focus, prompting stepped-up proposals on ways to finance these products.
May 30, 2019
In the first in a series of articles addressing each of the American Patients First blueprint's four strategies, Rick Kelly and Nisha Desai focus on “Increasing Competition”.
May 29, 2019
Jill Wechsler looks at the proposed new FDA rules to beef up regulatory resources and promote digital technologies to support the development and marketing of safe and innovative over-the-counter therapies.
May 15, 2019
FDA is examining and updating its programs for overseeing global operations and international affairs.
native1_300x100
киев доставка воды

progressive.ua

обращайтесь fashioncarpet.com.ua
lorem ipsum